MindWalk Holdings Corp. (HYFT)
| Market Cap | 61.59M |
| Revenue (ttm) | 20.70M |
| Net Income (ttm) | -9.03M |
| Shares Out | 49.67M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,174 |
| Open | 1.170 |
| Previous Close | 1.160 |
| Day's Range | 1.170 - 1.270 |
| 52-Week Range | 0.429 - 3.246 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+303.23%) |
| Earnings Date | Mar 12, 2026 |
About HYFT
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 202... [Read more]
Financial Performance
In fiscal year 2025, MindWalk Holdings's revenue was 24.52 million, an increase of 0.01% compared to the previous year's 24.52 million. Losses were -30.23 million, 15.8% more than in 2024.
Financial numbers in CAD Financial StatementsAnalyst Forecast
According to one analyst, the rating for HYFT stock is "Strong Buy" and the 12-month stock price target is $5.0.
News
MindWalk Holdings Earnings Call Transcript: Q3 2026
Revenue grew 52% YoY in Q3 2026, driven by U.S. expansion and the first recurring LensAI contract. Pipeline programs advanced, cash position remains strong, and asset-level financing is in progress.
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (Nasdaq: HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial re...
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single...
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will report fi...
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its ...
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
VICTORIA, British Columbia--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies ...
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its univ...
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its univ...
MindWalk Holdings Earnings Call Transcript: Q2 2026
Second quarter saw 54% revenue growth and a 94% increase in gross profit, driven by scalable AI-enabled programs and the divestiture of non-core assets. A strong cash position and new asset portfolio structure support continued investment and protect shareholders from dilution.
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
VICTORIA, British Columbia--(BUSINESS WIRE)---- $HYFT #ai--MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologi...
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025
AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a co...
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Tec...
MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R...
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran...
MindWalk Announces Share Repurchase Program
AUSTIN, Texas--(BUSINESS WIRE)---- $hyft #AI--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in Mind...
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancement of its AI-desi...
MindWalk Holdings Earnings Call Transcript: Q1 2026
Record Q1 revenue and margin expansion were achieved, with improved operating results and a strengthened balance sheet following the Netherlands divestiture. The rebranding to MindWalk Inc. and focus on AI-driven platforms position the company for scalable growth and new partnerships.
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-...
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announ...
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global In...
ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discove...
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discove...
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.
WASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)--Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced...
MindWalk Holdings Earnings Call Transcript: Q4 2025
Record Q4 revenue and margin expansion driven by BioStrand's triple-digit growth and operational efficiency. Major partnerships, AI platform advances, and a strong cash position set the stage for continued growth, with divestiture and rebranding to sharpen focus.
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (“IPA”, “Company”, “we” or “us”) (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-gen...